Last reviewed · How we verify
Cetavlon (CETRIMIDE)
At a glance
| Generic name | CETRIMIDE |
|---|---|
| Drug class | cetrimide |
| Target | Dynamin-1 |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial (PHASE2)
- IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers (NA)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) (PHASE3)
- Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG (PHASE2)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU) (PHASE3)
- Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa
- Suprapubic Aspiration Versus Urinary Catheterization In Neonates. (NA)
- Single-centre Study to Investigate Safety and Efficacy of Tri-Solfen in Wound Debridement (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetavlon CI brief — competitive landscape report
- Cetavlon updates RSS · CI watch RSS